Health Care | Pharmaceuticals, Biotechnology & Life Sciences | Biotechnology
NASDAQ | Common Stock
Celgene Corporation, a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of cancer and inflammatory diseases worldwide.
It offers REVLIMID, an oral immunomodulatory drug for multiple myeloma (MM), myelodysplastic syndromes (MDS), and mantle cell lymphoma; POMALYST/IMNOVID to treat multiple myeloma; OTEZLA, a small-molecule inhibitor of phosphodiesterase 4 for psoriatic arthritis and psoriasis; and ABRAXANE to treat breast, non-small cell lung, pancreatic, and gastric cancers.
The company's products also include IDHIFA for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (rrAML) with an isocitrate dehydrogenase-2 mutation; VIDAZA, a pyrimidine nucleoside analog for intermediate-2 and high-risk MDS, chronic myelomonocytic leukemia, and AML; THALOMID to treat patients with MM; and ISTODAX, an epigenetic modifier.
Its preclinical and clinical-stage product candidates include small molecules, biologics, and cell therapies for immune-inflammatory diseases, myeloid diseases, epigenetics, protein homeostasis, and immuno-oncology.
The company has agreements with BeiGene, Ltd; Acceleron Pharma, Inc.; Agios Pharmaceuticals, Inc.; bluebird bio, Inc.; Lycera Corp.; Juno Therapeutics, Inc.; EXSCIENTIA LTD.; and IMIDomics SL, as well as immuno-oncology collaboration with Sutro Biopharma.
The company also has strategic collaboration with Skyhawk Therapeutics, Inc. to discover and develop novel small molecules that modulate RNA splicing.
Celgene Corporation was founded in 1980 and is headquartered in Summit, New Jersey.
As of November 20, 2019, Celgene Corporation operates as a subsidiary of Bristol-Myers Squibb Company.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Jan 31, 19 | 2.39 Increased by +19.50% | 2.32 Increased by +3.02% |
| Oct 25, 18 | 2.29 Increased by +19.90% | 2.22 Increased by +3.15% |
| Jul 26, 18 | 2.16 Increased by +18.68% | 2.11 Increased by +2.37% |
| May 4, 18 | 2.05 Increased by +22.02% | 1.96 Increased by +4.59% |
| Jan 25, 18 | 2.00 Increased by +274.04% | 1.97 Increased by +1.52% |
| Oct 26, 17 | 1.91 Increased by +793.36% | 1.87 Increased by +2.14% |
| Jul 27, 17 | 1.82 Increased by +143.84% | 1.78 Increased by +2.25% |
| Apr 27, 17 | 1.68 Increased by +69.47% | 1.63 Increased by +3.07% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 19 | 4.52 B Increased by +16.14% | 1.69 B Increased by +56.28% | Increased by +37.41% Increased by +34.57% |
| Jun 30, 19 | 4.40 B Increased by +15.36% | 1.57 B Increased by +50.33% | Increased by +35.70% Increased by +30.31% |
| Mar 31, 19 | 4.03 B Increased by +13.76% | 1.54 B Increased by +82.62% | Increased by +38.39% Increased by +60.53% |
| Dec 31, 18 | 4.04 B Increased by +15.91% | 1.07 B Increased by +1.42 K% | Increased by +26.58% Increased by +1.24 K% |
| Sep 30, 18 | 3.89 B Increased by +18.23% | 1.08 B Increased by +6.18% | Increased by +27.80% Decreased by -10.19% |
| Jun 30, 18 | 3.81 B Increased by +16.71% | 1.04 B Decreased by -1.51% | Increased by +27.40% Decreased by -15.61% |
| Mar 31, 18 | 3.54 B Increased by +19.53% | 846.00 M Decreased by -10.10% | Increased by +23.91% Decreased by -24.78% |
| Dec 31, 17 | 3.48 B Increased by +16.86% | -81.00 M Decreased by -118.89% | Decreased by -2.33% Decreased by -116.16% |